The 12th AOHUPO Congress, the 8th AOAPO Congress, the third Global Summit of the π-HuB International Big Science Program and the 13th CNHUPO Congress will be held on October 11-14, 2025 in Guangzhou. As a leader in clinical proteomics, ProteinT will make a major appearance at this international event, presenting the latest breakthroughs in frontier technology, product translation and clinical solutions, and discussing new trends in precision medicine with experts worldwide. We sincerely invite experts, scholars and partners to visit booth B02.

The congress will bring together nearly 200 experts and scholars from more than 20 countries and regions, with 30+ thematic forums covering basic research, frontier technology, data and computing, and medical application and industrialization.

Featured products and solutions.

01 Multi-cancer risk screening — PT-ESMC™. Using LC-MS/MS whole-proteome testing on blood samples combined with a proprietary screening model, it simultaneously assesses the risk of lung, liver, colorectal, gastric and pancreatic cancers, providing a non-invasive tool for population screening and early intervention.

02 Stage I lung-cancer recurrence-risk prediction — PT-L1™. Based on LC-MS/MS tumor-tissue proteomics combined with ProteinT's proprietary stage I lung-cancer recurrence-risk model, it assesses the 5-year post-operative recurrence risk, helping physicians identify high-risk patients earlier for precise follow-up.

03 Dual-omics targeted-drug solution — TargetSelect™. Combining proteomics and genomics, it improves the accuracy of targeted-drug selection and increases patient benefit.